Clinical Trial Update: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of Batiraxcept (AVB-S6-500) plus paclitaxel in platinum-resistant recurrent ovarian cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Batiraxcept (AVB-S6-500)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Aravive, Inc. | Conditions: Platinum-resistant Ovarian Cancer | Phase 3 | Status: TERMINATED